AVT Stock Recent News

Avnet remains a Hold as sluggish OEM demand and high inventory persist, but signs of stability are emerging, especially in Asia. Q3 2025 results were unremarkable but solid, with strong cash flow, stable margins, and EPS outperforming guidance despite revenue declines. Valuation is fair and discounted versus peers, reflecting manageable headwinds; not a value trap, but not a clear bargain either.

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

REYKJAVIK,  ICELAND and LONDON, UK (June 23, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein.

Avnet (AVT) reported earnings 30 days ago. What's next for the stock?

PHOENIX--(BUSINESS WIRE)-- #Avnet--Avnet declares regular quarterly dividend.

Explore Avnet's (AVT) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

AVT's third-quarter fiscal 2025 results reflect the company's declining sales and shrinking margins.

Avnet, Inc. (NASDAQ:AVT ) Q3 2025 Earnings Call April 30, 2025 12:00 PM ET Company Participants Joe Burke - Vice President, Investor Relations Phil Gallagher - Chief Executive Officer Ken Jacobson - Chief Financial Officer Conference Call Participants Joe Quatrochi - Wells Fargo William Stein - Truist Wamsi Mohan - Bank of America Operator Greetings and welcome to the Avnet Third Quarter Fiscal Year 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.

The headline numbers for Avnet (AVT) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Avnet (AVT) came out with quarterly earnings of $0.84 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $1.10 per share a year ago.